LobbyingPear Therapeutics lobbying by quarter
Pear Therapeutics's latest lobbying report covers Q2 2023, at under $5,000. Its first report covers Q4 2022; the issues it reports most are Health Issues and Budget/Appropriations.
Pear Therapeutics
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $50K | 2 |
| Q1 2023 | $30K | 2 |
| Q2 2023 | $0 | 1 |
| Q3 2023 | $0 | 0 |
| Q4 2023 | $0 | 0 |
| Q1 2024 | $0 | 0 |
| Q2 2024 | $0 | 0 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$53.3K · 4 reports
- Budget and appropriations$13.3K · 2 reports
- Medicare and Medicaid$13.3K · 2 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES4 reports
- SENATE4 reports
- Health & Human Services, Dept of (HHS)2 reports
Firms it paid
| Firm | ||
|---|---|---|
| Bluebird Strategies | $40K | 3 quarters |
| K&L Gates | $40K | 2 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| MICHAEL WILLIAM EVANS | Democratic Chief Counsel and Deputy Staff Director, U.S. Senate Committee on Finance, | Q4 2022 |
| SCOTT J. GELBMAN | Staff Assistant/Legislative Correspondent/Legislative Assistant, Senator Chuck Schumer | Q4 2022 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 23/04/18for Q2 2023 | Bluebird Strategies | Under $5,000 |
| 23/04/18for Q1 2023 | Bluebird Strategies | $10K |
| 23/04/17for Q1 2023 | K&L Gates | $20K |
| 23/01/18for Q4 2022 | K&L Gates | $20K |
| 23/01/16for Q4 2022 | Bluebird Strategies | $30K |